Core Insights - China Medical System Holdings Limited (CMS) announced the launch of ruxolitinib phosphate cream (Lumirix), the first topical JAK inhibitor approved in China for vitiligo treatment, marking a significant advancement in the treatment landscape for this condition [1][2][3] Group 1: Product Launch and Market Access - Ruxolitinib phosphate cream has received initial prescriptions for vitiligo patients across 30 provincial-level regions, covering around 1,000 medical institutions [1] - The product is available in over 1,300 offline drugstores and on the JD.com e-commerce platform, enhancing accessibility for patients [1] - The product's approval and subsequent prescription issuance occurred within 1.5 months, demonstrating efficient collaboration among CMS, regulatory authorities, and business partners [3] Group 2: Regulatory Support and Clinical Data - The rapid commercialization of the product reflects strong operational capabilities of CMS and support from China's regulatory reforms, which facilitate patient access to innovative drugs [2] - The product has accumulated real-world clinical data under pilot applications, significantly accelerating its clinical registration and approval timelines [2] Group 3: Strategic Importance and Future Prospects - The launch of ruxolitinib phosphate cream is expected to enhance Dermavon's brand value and comprehensive dermatology solutions, benefiting more vitiligo patients [4] - The product fills a significant gap in targeted drug treatment for vitiligo, addressing the limitations of existing therapies [7] - CMS aims to continue improving the accessibility of the product to safeguard public skin health through innovation [4][7]